Progress of Oncolytic Virotherapy for Neuroblastoma

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2022 Dec 5

PMID 36467495

Authors

Xiao-Tong Chen

Shu-Yang Dai

Yong Zhan

Ran Yang

De-Qian Chen

Yi Li

En-Qing Zhou

Rui Dong

Affiliations

Soon will be listed here.

Abstract

As a neuroendocrine tumor derived from the neural crest, neuroblastoma (NB) is the most common extracranial solid tumor in children. The prognosis in patients with low- and intermediate-risk NB is favorable while that in high-risk patients is often detrimental. However, the management of the considerably large proportion of high-risk patients remains challenging in clinical practice. Among various new approaches, oncolytic virus (OV) therapy offers great advantages in tumor treatment, especially for high-risk NB. Genetic modified OVs can target NB specifically without affecting normal tissue and avoid the widespread drug resistance issue in anticancer monotherapy. Meanwhile, its safety profile provides great potential in combination therapy with chemo-, radio-, and immunotherapy. The therapeutic efficacy of OV for NB is impressive from bench to bedside. The effectiveness and safety of OVs have been demonstrated and reported in studies on children with NB. Furthermore, clinical trials on some OVs (Celyvir, Pexa-Vec (JX-594) and Seneca Valley Virus (NTX-010)) have reported great results. This review summarizes the latest evidence in the therapeutic application of OVs in NB, including those generated in cell lines, animal models and clinical trials.

Citing Articles

Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.

Chu Y, Tian M, Saini U, Ayala-Cuesta J, Klose K, Mendelowitz A Mol Ther Oncol. 2025; 33(1):200927.

PMID: 39895691 PMC: 11783442. DOI: 10.1016/j.omton.2024.200927.

Neuroblastoma-A Review of Combination Immunotherapy.

Pieniazek B, Cencelewicz K, Bzdziuch P, Mlynarczyk L, Lejman M, Zawitkowska J Int J Mol Sci. 2024; 25(14).

PMID: 39062971 PMC: 11276848. DOI: 10.3390/ijms25147730.

Advances and challenges in gene therapy strategies for pediatric cancer: a comprehensive update.

Moaveni A, Amiri M, Shademan B, Farhadi A, Behroozi J, Nourazarian A Front Mol Biosci. 2024; 11:1382190.

PMID: 38836106 PMC: 11149429. DOI: 10.3389/fmolb.2024.1382190.

The Neuroblastoma Microenvironment, Heterogeneity and Immunotherapeutic Approaches.

Polychronopoulos P, Bedoya-Reina O, Johnsen J Cancers (Basel). 2024; 16(10).

PMID: 38791942 PMC: 11119056. DOI: 10.3390/cancers16101863.

Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.

Chen C, Hu C, He B, Bai Y, He F, Li S Biosensors (Basel). 2023; 13(10).

PMID: 37887113 PMC: 10605222. DOI: 10.3390/bios13100920.

References

Noyce R, Bondre D, Ha M, Lin L, Sisson G, Tsao M . Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011; 7(8):e1002240. PMC: 3161989. DOI: 10.1371/journal.ppat.1002240. View

Miller J, Bidula S, Jensen T, Reiss C . Cytokine-modified VSV is attenuated for neural pathology, but is both highly immunogenic and oncolytic. Int J Interferon Cytokine Mediat Res. 2010; 1:15-32. PMC: 2895263. DOI: 10.2147/ijicmr.s6776. View

Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z . Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells. Biochem Biophys Res Commun. 2017; 491(1):134-139. DOI: 10.1016/j.bbrc.2017.07.062. View

Leis K, Baska A, Bereznicka W, Marjanska A, Mazur E, Lewandowski B . Resveratrol in the treatment of neuroblastoma: a review. Rev Neurosci. 2020; . DOI: 10.1515/revneuro-2020-0021. View

Ogbomo H, Zemp F, Lun X, Zhang J, Stack D, Rahman M . Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One. 2013; 8(6):e66825. PMC: 3677932. DOI: 10.1371/journal.pone.0066825. View

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View

Mackie R, Stewart B, Brown S . Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet. 2001; 357(9255):525-6. DOI: 10.1016/S0140-6736(00)04048-4. View

Yanagi Y . [The cellular receptor for measles virus]. Uirusu. 2002; 51(2):201-8. View

Mazar J, Li Y, Rosado A, Phelan P, Kedarinath K, Parks G . Zika virus as an oncolytic treatment of human neuroblastoma cells requires CD24. PLoS One. 2018; 13(7):e0200358. PMC: 6059425. DOI: 10.1371/journal.pone.0200358. View

10.

Cassady K, Haworth K, Jackson J, Markert J, Cripe T . To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses. Viruses. 2016; 8(2). PMC: 4776198. DOI: 10.3390/v8020043. View

11.

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M . Neuroblastoma. Jpn J Clin Oncol. 2018; 48(3):214-241. DOI: 10.1093/jjco/hyx176. View

12.

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

13.

Ben-Yakar A . High-Content and High-Throughput In Vivo Drug Screening Platforms Using Microfluidics. Assay Drug Dev Technol. 2019; 17(1):8-13. DOI: 10.1089/adt.2018.908. View

14.

Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F . Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J Virol. 2011; 85(24):13114-23. PMC: 3233137. DOI: 10.1128/JVI.05759-11. View

15.

Gil M, Bieniasz M, Seshadri M, Fisher D, Ciesielski M, Chen Y . Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer. 2011; 105(10):1512-21. PMC: 3242530. DOI: 10.1038/bjc.2011.429. View

16.

Bauer D, Pereboeva L, Gillespie G, Cloud G, Elzafarany O, Langford C . Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma. J Immunol Res. 2016; 2016:2568125. PMC: 5005549. DOI: 10.1155/2016/2568125. View

17.

Ganesh S, Gonzalez-Edick M, Gibbons D, Van Roey M, Jooss K . Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clin Cancer Res. 2008; 14(12):3933-41. DOI: 10.1158/1078-0432.CCR-07-4732. View

18.

Mace A, Ganly I, Soutar D, Brown S . Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008; 30(8):1045-51. DOI: 10.1002/hed.20840. View

19.

Mahller Y, Vaikunth S, Ripberger M, Baird W, Saeki Y, Cancelas J . Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res. 2008; 68(4):1170-9. PMC: 2855837. DOI: 10.1158/0008-5472.CAN-07-2734. View

20.

Lun X, Ruan Y, Jayanthan A, Liu D, Singh A, Trippett T . Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013; 7(5):944-54. PMC: 5528451. DOI: 10.1016/j.molonc.2013.05.004. View